Company Spotlight:Expedition Medicines
Cambridge has seen ambition parade itself for decades. Expedition Medicines arrived without the parade. No slogans, no volume, no borrowed confidence. Just a reaction first mindset aimed at the hardest truth in biotech. Undruggable proteins were never impossible. They were premature. The chemistry was early. The data was thin. The compute was guessing. Now the math is mature, the experiments are loud, and the molecules answer back.
Expedition Medicines was founded in 2022 and incubated quietly for three years inside Flagship Pioneering before its October 2025 launch with $50M in seed capital. Cambridge, MA is home base. Headcount sits in the 11 to 50 range, but the footprint is larger if you count ambition. The company is built around reaction first covalent chemistry, starting with chemoproteomics to map more than 20,000 reactive sites across the human proteome. Quantum chemistry explains what reacts and why. Generative AI learns the patterns and scales the search. This is not hype layered on biology. It is biology driving the computation.
Molly Gibson serves as CEO and Co-Founder, carrying hard earned instincts from building Generate:Biomedicines and Lila Sciences. Noubar Afeyan is Co-Founder and Board Director, bringing the long cycle patience of Flagship Pioneering. Nathan Stebbins, Co-Founder and Chief Strategy Officer, frames the narrative with discipline. Dean Stamos, Co Founder and Chief Scientific Officer for Chemistry and Proteomics, and Todd Kinsella, Chief Scientific Officer for Drug Discovery and Translation, both arrive from Vividion, acquired by Bayer for $1.5B in 2021. Marie Yurkovich leads strategy and operations. Henry van den Bedem is CTO, bringing machine learning depth from Atomwise. Geoffrey von Maltzahn is Co-Founder, Flagship General Partner, and Board Director, bridging science and scale.
The board signals seriousness. Michael Nally, CEO of Generate:Biomedicines. Gary Pisano from Harvard Business School. Rupert Vessey, former President of R&D at Bristol Myers Squibb and now Chief Scientist at Flagship. Thermo Fisher joined as both equity investor and technology partner, accelerating mass spectrometry throughput to field leading levels.
External validation came early. A multi-target partnership with Pfizer focused on prostate cancer confirmed platform confidence beyond the cap table. Multiple oncology and immunology programs are active. The first development candidate is expected in H1 2026. This is momentum without noise.
Expedition Medicines is hiring Senior ML Scientists, DMPK specialists, computational biologists, and medicinal chemists who like clean data, hard problems, and long arcs. This is an expedition by definition. Map precisely. Move deliberately. Bring back something real.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing, together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.
Full rundowns live www.devcuration.com
If engineering peace of mind is what you crave, Vention is your zen.